Quest Diagnostics (DGX) Reports In-Line Q2 EPS; Trims FY12 Revs Growth Outlook
Quest Diagnostics, Inc. (NYSE: DGX) reported Q2 EPS of $1.17, in-line with the analyst estimate of $1.17. Revenue for the quarter came in at $1.91 million versus the consensus estimate of $1.94 million.
Sees FY12 revenues to grow between 1% and 2%, compared to the prior outlook of between 2% and 2.5%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Sees FY12 revenues to grow between 1% and 2%, compared to the prior outlook of between 2% and 2.5%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.